mTOR pathway in colorectal cancer: an update

  • Francipane M
  • Lagasse E
N/ACitations
Citations of this article
87Readers
Mendeley users who have this article in their library.

Abstract

The mammalian target of rapamycin (mTOR) has emerged as a potential target for drug development, particularly due to the fact that it plays such a crucial role in cancer biology. In addition, next-generation mTOR inhibitors have become available, marking an exciting new phase in mTOR-based therapy. However, the verdict on their therapeutic effectiveness remains unclear. Here we review phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR signaling as one of the primary mechanisms for sustaining tumor outgrowth and metastasis, recent advances in the development of mTOR inhibitors, and current studies addressing mTOR activation/inhibition in colorectal cancer (CRC). We will also discuss our recent comparative study of different mTOR inhibitors in a population of colon cancer stem cells (CSCs), and current major challenges for achieving individualized drug therapy using kinase inhibitors.

Cite

CITATION STYLE

APA

Francipane, M. G., & Lagasse, E. (2015). mTOR pathway in colorectal cancer: an update. Oncotarget, 5(1). https://doi.org/10.18632/oncotarget.1548

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free